Neurotech Pharmaceuticals, Inc.
Paul Brannelly serves as the Chief Financial Officer at Neurotech Pharmaceuticals, Inc. and Ribon Therapeutics, bringing extensive financial leadership experience from previous roles including Executive Vice President and Chief Financial Officer at Collegium Pharmaceutical, Inc. and Senior Vice President of Finance & Administration at Karyopharm Therapeutics Inc. In earlier career phases, Paul held the position of Vice President of Finance at Verastem. Academic credentials include a degree from UMass Amherst, earned between 1991 and 1995, alongside foundational education at Boston Latin School.
This person is not in any offices
Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has spent years developing the science, technology, team and manufacturing behind NT-501. As a result of a unique partnership and clear direction, we are focused on bringing a long-term treatment to Macular Telangiectasia (MacTel) patients. Our team is focused on bringing to market this treatment designed to slow the progression of MacTel and the vision impairments it causes in patients who don't have another treatment option. Our goal is to help these patients sustain their quality of life.